top of page
Search

Sentante Secures €6 Million in New Funding to RevolutionizeEndovascular Care

Sentante, a pioneering medical device company headquartered in Lithuania,

announces the closing of a €6 million seed funding round led by Practica Capital

with participation of EIC fund. The company will use the proceeds from the financing

for the planned clinical trial of the Sentante robotic system and preparation of

commercial launch in targeted international markets. 


„We appreciate the trust and support from our new investors to help us reach our

critical milestones. Sentante will revolutionize the way endovascular procedures are

performed and we are looking forward to introducing our robotic system into clinical

practice,“ said Edvardas Satkauskas, co-founder and CEO of Sentante. “Our

innovative robotic technology will digitize and improve the procedure by empowering

physicians to work with better accuracy, precision, and safety.” 


Endovascular management of cardiovascular diseases, such as stroke, heart

attacks, peripheral artery disease, involves over six million procedures annually.

Despite the market's size and innovations in the field, the procedure remains largely unchanged for over four decades. Physicians typically operate next to an X-ray

source while wearing heavy lead aprons, manually navigating catheters and

guidewires inserted into the patient's vascular system. This method poses a

heightened risk of medical errors and complications due to the non-ergonomic

workspace and serious occupational hazards from prolonged X-ray exposure.


Sentante will be easily incorporated into existing treatment workflow, as it uses the

same medical devices as in a manual procedure. „We look forward to the initiation of

the first-in-human clinical study later in 2024, marking a pivotal milestone that will

showcase Sentante's capabilities in peripheral vascular interventions. “ said Dr.

Tomas Baltrunas, co-founder and Chief Medical Officer of the Company. „Controlled

intuitively via conventional endovascular devices as the interface, the Sentante

robotic system senses operators' movements, providing a near-natural haptic forcefeedback experience. Even when working remotely, I can experience the same

sensation of catheter and guidewire resistance as if I were physically present beside

the patient"


"We are thrilled to partner with Sentante, a company that aligns perfectly with our

philosophy of supporting transformative innovations. With their unique teleoperated

endovascular intervention system, Sentante is set to redefine surgical practices

globally, improving both patient outcomes and the well-being of medical

professionals. This investment underscores our commitment to advancing healthcare

technologies that have the potential to create a significant, positive impact

worldwide", said Tomas Andriuškevičius, partner at Practica Capital.

 

Svetoslava Georgieva, Chair of the EIC Fund Board, said: “The EIC Fund aims at

backing European innovators in scaling their journey and Sentante is a great

example of how the European Union is helping top innovators. The EIC Fund's

ambitious commitment, alongside other investors, is an important step to boost their

development.”  

Sentante remains dedicated to advancing the landscape of endovascular care

offering a transformative solution that promises to redefine medical practice globally.




 -

 

About Sentante 

Sentante is an innovative teleoperated robotic system developed by UAB Inovatyvi

Medicina. It allows an entire endovascular intervention to be performed remotely,

from a different room, so physicians and entire medical team can work without being

exposed to harmful X-ray radiation. In the future, Sentante will allow physicians to

perform endovascular treatment from a remote hospital, eliminating the need for

physical patient transfer. This innovation bears profound significance, particularly in

critical cases such as stroke, where each passing minute significantly impacts the

chances of good outcome. 


About Practica Capital 

Practica Capital is an early-stage VC dedicated to backing Baltic founders. The firm

has been invested exclusively in tech potential in the Baltic States for over 10 years.

Practica Capital back great founders in their ambition in seed, selected pre-seed

and Series A stages and partnering with them as company builders. Practica Capital

manages four funds with more than €130m in AUM. To date the firm made over 60

investments, including great companies like Atrandi, Oxipit, Biomatter Designs,

PVcase, TransferGo, Interactio, Eneba, Ovoko, CGtrader and others. Find out more:


About EIC Fund 

The European Innovation Council Fund from the European Commission is an

agnostic Fund: it invests across all technologies and verticals, and all EU countries

and countries associated to Horizon Europe. It provides the investment component

of the EIC Accelerator blended finance. The European Investment Bank acts as

investment adviser to the EIC Fund.  

The EIC Fund aims to fill a critical financing gap and its main purpose is to support

companies in the development and commercialization of disruptive technologies,

bridging with and crowding in market players, and further sharing risk by building a

large network of capital providers and strategic partners suitable for co-investments

and follow-on funding.  

The Fund has – amongst others - the ambition to reduce the innovation divide

among EU countries.

22 views0 comments

Recent Posts

See All

Comments


bottom of page